Application of standardised effect sizes to hospital discharge outcomes for people with diabetes.


Journal

BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682

Informations de publication

Date de publication:
07 07 2020
Historique:
received: 27 09 2019
accepted: 25 06 2020
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 5 1 2021
Statut: epublish

Résumé

Patients with diabetes are at an increased risk of readmission and mortality when discharged from hospital. Existing research identifies statistically significant risk factors that are thought to underpin these outcomes. Increasingly, these risk factors are being used to create risk prediction models, and target risk modifying interventions. These risk factors are typically reported in the literature accompanied by unstandardized effect sizes, which makes comparisons difficult. We demonstrate an assessment of variation between standardised effect sizes for such risk factors across care outcomes and patient cohorts. Such an approach will support development of more rigorous risk stratification tools and better targeting of intervention measures. Data was extracted from the electronic health record of a major tertiary referral centre, over a 3-year period, for all patients discharged from hospital with a concurrent diagnosis of diabetes mellitus. Risk factors selected for extraction were pre-specified according to a systematic review of the research literature. Standardised effect sizes were calculated for all statistically significant risk factors, and compared across patient cohorts and both readmission & mortality outcome measures. Data was extracted for 46,357 distinct admissions patients, creating a large dataset of approximately 10,281,400 data points. The calculation of standardized effect size measures allowed direct comparison. Effect sizes were noted to be larger for mortality compared to readmission, as well as for being larger for surgical and type 1 diabetes cohorts of patients. The calculation of standardised effect sizes is an important step in evaluating risk factors for healthcare events. This will improve our understanding of risk and support the development of more effective risk stratification tools to support patients to make better informed decisions at discharge from hospital.

Sections du résumé

BACKGROUND
Patients with diabetes are at an increased risk of readmission and mortality when discharged from hospital. Existing research identifies statistically significant risk factors that are thought to underpin these outcomes. Increasingly, these risk factors are being used to create risk prediction models, and target risk modifying interventions. These risk factors are typically reported in the literature accompanied by unstandardized effect sizes, which makes comparisons difficult. We demonstrate an assessment of variation between standardised effect sizes for such risk factors across care outcomes and patient cohorts. Such an approach will support development of more rigorous risk stratification tools and better targeting of intervention measures.
METHODS
Data was extracted from the electronic health record of a major tertiary referral centre, over a 3-year period, for all patients discharged from hospital with a concurrent diagnosis of diabetes mellitus. Risk factors selected for extraction were pre-specified according to a systematic review of the research literature. Standardised effect sizes were calculated for all statistically significant risk factors, and compared across patient cohorts and both readmission & mortality outcome measures.
RESULTS
Data was extracted for 46,357 distinct admissions patients, creating a large dataset of approximately 10,281,400 data points. The calculation of standardized effect size measures allowed direct comparison. Effect sizes were noted to be larger for mortality compared to readmission, as well as for being larger for surgical and type 1 diabetes cohorts of patients.
CONCLUSIONS
The calculation of standardised effect sizes is an important step in evaluating risk factors for healthcare events. This will improve our understanding of risk and support the development of more effective risk stratification tools to support patients to make better informed decisions at discharge from hospital.

Identifiants

pubmed: 32635913
doi: 10.1186/s12911-020-01169-z
pii: 10.1186/s12911-020-01169-z
pmc: PMC7339522
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

150

Subventions

Organisme : HDR UK - Medical Research Council
ID : HDR-3001
Pays : International
Organisme : Department of Health [UK]
Pays : International
Organisme : Chief Scientist Office [UK]
Pays : International
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Références

Endocr Pract. 2016 Oct;22(10):1204-1215
pubmed: 27732098
Diabet Med. 2005 Jan;22(1):107-9
pubmed: 15606701
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1122-1129
pubmed: 29319819
Diabetes Care. 2006 Apr;29(4):805-10
pubmed: 16567819
J Vasc Surg. 2018 Mar;67(3):876-886
pubmed: 29017807
J Diabetes Complications. 2017 Aug;31(8):1332-1339
pubmed: 28571933
Eur Heart J Acute Cardiovasc Care. 2019 Apr;8(3):218-230
pubmed: 28691497
J Exp Psychol Gen. 2012 Feb;141(1):2-18
pubmed: 21823805
Biol Rev Camb Philos Soc. 2007 Nov;82(4):591-605
pubmed: 17944619
Med Care. 2006 Mar;44(3):292-6
pubmed: 16501402
Restor Dent Endod. 2013 Feb;38(1):52-4
pubmed: 23495371
J Diabetes Sci Technol. 2012 Sep 01;6(5):1045-52
pubmed: 23063030
Clin Orthop Relat Res. 2014 Nov;472(11):3570-5
pubmed: 25138473
J Diabetes Complications. 2017 Dec;31(12):1681-1685
pubmed: 28951043
J Diabetes Complications. 2019 May;33(5):398-405
pubmed: 30878296
Clin Diabetes Endocrinol. 2017 Mar 22;3:3
pubmed: 28702257
J Diabetes Complications. 2017 Jan;31(1):122-127
pubmed: 27838101

Auteurs

Tim Robbins (T)

Institute of Digital Healthcare, International Digital Laboratory, WMG, University of Warwick, Coventry, CV4 7AL, UK. drtrobbins@gmail.com.
Warwickshire Institute for the Study of Diabetes, Endocrinology & Metabolism, University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge Road, Coventry, CV2 2DX, UK. drtrobbins@gmail.com.

Sarah N Lim Choi Keung (SN)

Institute of Digital Healthcare, International Digital Laboratory, WMG, University of Warwick, Coventry, CV4 7AL, UK.

Sailesh Sankar (S)

Warwickshire Institute for the Study of Diabetes, Endocrinology & Metabolism, University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge Road, Coventry, CV2 2DX, UK.

Harpal Randeva (H)

Warwickshire Institute for the Study of Diabetes, Endocrinology & Metabolism, University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge Road, Coventry, CV2 2DX, UK.

Theodoros N Arvanitis (TN)

Institute of Digital Healthcare, International Digital Laboratory, WMG, University of Warwick, Coventry, CV4 7AL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH